{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:27:05Z","timestamp":1759422425710,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["FAPESP #2015\/03756-4"],"award-info":[{"award-number":["FAPESP #2015\/03756-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["#305068\/2014-8"],"award-info":[{"award-number":["#305068\/2014-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Frederico Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s42358-018-0040-x","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T08:55:36Z","timestamp":1543913736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors"],"prefix":"10.1186","volume":"58","author":[{"given":"Andrea Y.","family":"Shimabuco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celio R.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio C. B.","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana G.","family":"Waisberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina de M.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percival D.","family":"Sampaio-Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Goldenstein-Schainberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloisa","family":"Bonfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla G. S.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"40_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379\u201390.","journal-title":"Lancet"},{"issue":"6","key":"40_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D\u00e9sir\u00e9e van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u2013991.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"40_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.berh.2014.10.001","volume":"28","author":"PD Sampaio-Barros","year":"2014","unstructured":"Sampaio-Barros PD, van der Horst-Bruinsma IE. Adverse effects of TNF inhibitors in SpA: are they different from RA? Best Pract Res Clin Rheumatol. 2014;28:747\u201363.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"40_CR4","first-page":"61","volume":"35","author":"S Arends","year":"2017","unstructured":"Arends S, Brouwer E, Efde M, van der Veer E, Bootsma H, Wink F, et al. Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin Exp Rheumatol. 2017;35(1):61\u20138 Epub 2016 Oct 7.","journal-title":"Clin Exp Rheumatol"},{"key":"40_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36:801\u20138.","journal-title":"J Rheumatol"},{"key":"40_CR6","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69:2002\u20138.","journal-title":"Ann Rheum Dis"},{"key":"40_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/BOR.0b013e32835257c5","volume":"24","author":"S Arends","year":"2012","unstructured":"Arends S, van der Veer E, Kallenberg CG, Brouwer E, Spoorenberg A. Baseline predictors of response to TNF-\u03b1 blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol. 2012;24:290\u20138.","journal-title":"Curr Opin Rheumatol"},{"key":"40_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.berh.2011.11.006","volume":"25","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos X, Braun J. Spondyloarthritides. Best Pract Res Clin Rheumatol. 2011;25:825\u201342.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"40_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/art.22236","volume":"55","author":"F Cantini","year":"2006","unstructured":"Cantini F, Niccoli L, Benucci M, Chindamo D, Nannini C, Olivieri I, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum. 2006;55:812\u20136.","journal-title":"Arthritis Rheum"},{"key":"40_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie E, van der Heijde D, Uhlig T, Mikkelsen K, R\u00f8devand E, Koldingsnes W, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011;70:157\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"40_CR11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, \u00d8stergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149\u20135.","journal-title":"Ann Rheum Dis"},{"key":"40_CR12","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/ken334","volume":"47","author":"DJ Pradeep","year":"2008","unstructured":"Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C. Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford). 2008;47:1726\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"40_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s10354-010-0795-0","volume":"160","author":"G Haberhauer","year":"2010","unstructured":"Haberhauer G, Strehblow C, Fasching P. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr. 2010;160:220\u20134.","journal-title":"Wien Med Wochenschr"},{"key":"40_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/ard.2006.057745","volume":"66","author":"MK Vries de","year":"2007","unstructured":"de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis. 2007;66:133\u20134.","journal-title":"Ann Rheum Dis"},{"key":"40_CR15","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/ard.2009.109702","volume":"68","author":"MK Vries de","year":"2009","unstructured":"de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis. 2009;68:1787\u20138.","journal-title":"Ann Rheum Dis"},{"key":"40_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/ard.2007.073544","volume":"67","author":"LE Kristensen","year":"2008","unstructured":"Kristensen LE, G\u00fclfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the south Swedish arthritis treatment group register. Ann Rheum Dis. 2008;67:364\u20139.","journal-title":"Ann Rheum Dis"},{"key":"40_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","volume":"73","author":"KM Fagerli","year":"2014","unstructured":"Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, R\u00f8devand E, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis. 2014;73:132\u20137.","journal-title":"Ann Rheum Dis"},{"key":"40_CR18","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acr.20258","volume":"62","author":"LE Kristensen","year":"2010","unstructured":"Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken). 2010;62:1362\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"40_CR19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","volume":"74","author":"E Lie","year":"2015","unstructured":"Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandstr\u00f6m T, Askling J, Jacobsson LT, ARTIS Study Group. The effect of co-medication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis. 2015;74:970\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"40_CR20","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/art.39691","volume":"68","author":"MJ Nissen","year":"2016","unstructured":"Nissen MJ, Ciurea A, Bernhard J, Tamborrini G, Mueller R, Weiss B, et al. The effect of Comedication with a conventional synthetic disease-modifying Antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial Spondyloarthritis. Arthritis Rheumatol. 2016;68(9):2141\u201350.","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"40_CR21","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1002\/art.39772","volume":"68","author":"A Sepriano","year":"2016","unstructured":"Sepriano A, Ramiro S, van der Heijde D, \u00c1vila-Ribeiro P, Fonseca R, Borges J, et al. Effect of Comedication with conventional synthetic disease-modifying Antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with Spondyloarthritis: a prospective cohort study. Arthritis Rheumatol. 2016;68(11):2671\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"40_CR22","doi-asserted-by":"publisher","first-page":"862969","DOI":"10.1155\/2014\/862969","volume":"2014","author":"M Fabbroni","year":"2014","unstructured":"Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, et al. Drug retention rates and treatment discontinuation among anti-TNF-\u03b1 agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediat Inflamm. 2014;2014:862969.","journal-title":"Mediat Inflamm"},{"key":"40_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden Van der","year":"1984","unstructured":"Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"40_CR24","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.097774","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of Spondyloarthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:ii1\u2013ii44.","journal-title":"Ann Rheum Dis"},{"key":"40_CR25","first-page":"2286","volume":"21","author":"S Garret","year":"1994","unstructured":"Garret S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"40_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/rheumatology\/34.8.793","volume":"34","author":"A Calin","year":"1995","unstructured":"Calin A, Jones SD, Garrett SL, Kennedy LG. Bath ankylosing spondylitis functional index. Br J Rheumatol. 1995;34:793\u20134.","journal-title":"Br J Rheumatol"},{"key":"40_CR27","first-page":"1694","volume":"21","author":"TR Jenkinson","year":"1994","unstructured":"Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21:1694\u20138.","journal-title":"J Rheumatol"},{"key":"40_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"63","author":"LC Doward","year":"2003","unstructured":"Doward LC, Spoorenberg A, Cook A, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQol: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;63:20\u20136.","journal-title":"Ann Rheum Dis"},{"key":"40_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47\u201353.","journal-title":"Ann Rheum Dis"},{"doi-asserted-by":"crossref","unstructured":"Machado PM, Landew\u00e9 R, Heijde DV; Assessment of SpondyloArthritis international Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018 Feb 16: annrheumdis-2018-213184. [Epub ahead of print].","key":"40_CR30","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"40_CR31","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:R94.","journal-title":"Arthritis Res Ther"},{"key":"40_CR32","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/rheumatology\/kev001","volume":"54","author":"JL Rosales-Alexander","year":"2015","unstructured":"Rosales-Alexander JL, Aznar JB, Perez-Vicente S, Magro-Checa C. Drug survival of anti-tumour necrosis factor \u03b1 therapy: results from the Spanish - AR II study. Rheumatology (Oxford). 2015;54:1459\u201363.","journal-title":"Rheumatology (Oxford)"},{"key":"40_CR33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","volume":"47","author":"LC Coates","year":"2008","unstructured":"Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, et al. Real-life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford). 2008;47:897\u2013900.","journal-title":"Rheumatology (Oxford)"},{"key":"40_CR34","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/ar3054","volume":"12","author":"M Rudwaleit","year":"2010","unstructured":"Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12:R117.","journal-title":"Arthritis Res Ther"},{"key":"40_CR35","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/rheumatology\/keq377","volume":"50","author":"J Paccou","year":"2011","unstructured":"Paccou J, Solau-Gervais E, Houvenagel E, Salleron J, Luraschi H, Philippe P, et al. Efficacy in current practice of switching between anti-tumour necrosis factor- \u03b1 agents in spondyloarthropathies. Rheumatology (Oxford). 2011;50:714\u201320.","journal-title":"Rheumatology (Oxford)"},{"key":"40_CR36","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F Conti","year":"2007","unstructured":"Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"40_CR37","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3899\/jrheum.150389","volume":"42","author":"AV Heinonen","year":"2015","unstructured":"Heinonen AV, Aaltonen KJ, Joensuu JT, L\u00e4hteenm\u00e4ki JP, Pertovaara MI, Romu MK, et al. Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J Rheumatol. 2015;42(12):2339\u201346.","journal-title":"J Rheumatol"},{"issue":"5","key":"40_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.semarthrit.2016.11.004","volume":"46","author":"Virginia Villaverde-Garc\u00eda","year":"2017","unstructured":"Villaverde-Garc\u00eda V, Cobo-Ib\u00e1\u00f1ez T, Candelas-Rodr\u00edguez G, Seoane-Mato D, Campo-Fontecha PDD, Guerra M, et al. The effect of smoking on clinical and structural damage in patients with axial spondyloarthritis: A systematic literature review. Semin Arthritis Rheum. 2016;46(5):569\u2013583.","journal-title":"Seminars in Arthritis and Rheumatism"},{"doi-asserted-by":"crossref","unstructured":"Jones GT, Ratz T, Dean LE, Macfarlane GJ, Atzeni F. In axial spondyloarthritis, never smokers, ex-smokers and current smokers show a gradient of increasing disease severity - results from the Scotland registry for ankylosing spondylitis (SIRAS). Arthritis Care Res (Hoboken). 2017;69(9):1407\u20131413.","key":"40_CR39","DOI":"10.1002\/acr.23157"},{"issue":"2","key":"40_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00296-016-3590-4","volume":"37","author":"S Zhao","year":"2017","unstructured":"Zhao S, Challoner B, Khattak M, Moots RJ, Goodson NJ. Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. Rheumatol Int. 2017;37(2):239\u201344.","journal-title":"Rheumatol Int"},{"issue":"4","key":"40_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/rheumatology\/kev392","volume":"55","author":"B Glintborg","year":"2016","unstructured":"Glintborg B, H\u00f8jgaard P, Lund Hetland M, Steen Krogh N, Kollerup G, Jensen J, et al. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology (Oxford). 2016;55(4):659\u201368.","journal-title":"Rheumatology (Oxford)"},{"key":"40_CR42","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3899\/jrheum.110687","volume":"39","author":"M Benegas","year":"2012","unstructured":"Benegas M, Mu\u00f1oz-Gomariz E, Font P, Burgos-Vargas R, Chaves J, Palleiro D, et al. RESPONDIA group; ASPECT study group; REGISPONSER study group. Comparison of the clinical expression of patients with ankylosing spondylitis from Europe and Latin America. J Rheumatol. 2012;39:2315\u201320.","journal-title":"J Rheumatol"},{"key":"40_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s11926-014-0438-3","volume":"16","author":"CG Saad","year":"2014","unstructured":"Saad CG, Gon\u00e7alves CR, Sampaio-Barros PD. Seronegative arthritis in Latin America: a current review. Curr Rheumatol Rep. 2014;16:438.","journal-title":"Curr Rheumatol Rep"},{"key":"40_CR44","first-page":"33","volume":"54","author":"CL Kohem","year":"2014","unstructured":"Kohem CL, Bortoluzzo AB, Gon\u00e7alves CR, Braga da Silva JA, Ximenes AC, B\u00e9rtolo MB, et al. Profile of the use of disease modifying drugs in the Brazilian registry of Spondyloartrhritis. Braz J Rheumatol. 2014;54:33\u20137.","journal-title":"Braz J Rheumatol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-018-0040-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-018-0040-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-018-0040-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T19:07:52Z","timestamp":1575400072000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-018-0040-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["40"],"URL":"https:\/\/doi.org\/10.1186\/s42358-018-0040-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"type":"electronic","value":"2523-3106"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Local Ethics Committee on Human Research at the University of S\u00e3o Paulo (CAPPesq). All participants gave written informed consent in compliance with the Helsinki Declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"40"}}